In Europe, Briviact® (brivaracetam) is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
In the US, BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
As the safety of BRIVIACT injection in pediatric patients has not been established, BRIVIACT injection is indicated for the
treatment of partial-onset seizures only in adult patients (16 years of age and older).
Prescribing information Europe
For availability of Briviact® in other countries, please consult our local websites.